Lifera
Lifera is a PIF-owned Saudi biopharmaceutical company operating SaudiBio for aseptic drug product CDMO manufacturing and Lifera Omics for genomic testing and bioinformatics, serving global pharmaceutical clients and regional healthcare providers.
- Company typePrivate
- Founded2023
- HeadquartersRiyadh, Saudi Arabia
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Lifera does
Lifera is a biopharmaceutical company established in June 2023 by Saudi Arabia's Public Investment Fund (PIF) to develop the Kingdom's domestic biopharmaceutical manufacturing capacity and enable the National Biotechnology Strategy under Vision 2030. The company is wholly owned by PIF (Saudi Arabia's sovereign wealth fund) and operates from Riyadh. It serves global pharmaceutical clients seeking to localize drug manufacturing in Saudi Arabia and the MENA region, as well as healthcare providers requiring genomic testing and precision medicine services. Lifera runs two core business units: Biomanufacturing, via subsidiary SaudiBio, focused on sterile and aseptic drug product and drug substance manufacturing; and Lifera Omics (MultiOmics), providing high-throughput genetic testing, bioinformatics, and research services.
The Biomanufacturing platform centers on the SaudiBio facility in Sudair Industrial City, 110 km north of Riyadh, built on a 30,000 sqm plot with expansion potential. Plant 1 features isolator-based, fully automated formulation and filling under cGMP, with capacity to produce up to 120 million annual units across vials (liquid and lyophilized) in 2R–50R formats, pre-filled syringes, and cartridges. Equipment is sourced from premium global suppliers including Syntegon, Groninger, SKAN, and Pierre Guerin, with commissioning targeted for 2027 under EMA Annex 1 and SFDA standards. The Lifera Omics business operates a proprietary biodatabank with over 800,000 patients (60,000+ Saudi Arabian) and over 70 million unique variants, supporting genomics, multiomic testing, and AI-enabled drug discovery focused on disease areas endemic to MENA populations.
Lifera's revenue model combines (1) CDMO services — manufacturing fees, technology transfer agreements, and long-term supply contracts — with global pharmaceutical partners (anchored by a seven-year insulin localization arrangement with Novo Nordisk, a Jamjoom Pharma 51/49 joint venture for vaccines/biologics/biosimilars, and exploratory MoUs with Pfizer, Sanofi, and MSD), and (2) genomic and multiomic testing, bioinformatics, and research services delivered to healthcare providers, hospitals, and biopharma clients. Pricing is enterprise quote-based and not publicly disclosed. Go-to-market is direct B2B engagement, supplemented by event-driven partnership announcements such as those made at the Global Health Exhibition 2025.
Lifera firmographics
Firmographics- Name
- Lifera
- Legal name
- Lifera
- Website
- https://lifera.com.sa
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Lifera is a PIF-owned Saudi biopharmaceutical company operating SaudiBio for aseptic drug product CDMO manufacturing and Lifera Omics for genomic testing and bioinformatics, serving global pharmaceutical clients and regional healthcare providers.
- Ownership category
- akta.pro rank
Lifera industry classification
Industry- Product category
- Biopharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where Lifera is headquartered
LocationHeadquarters
- HQ city
- Riyadh
- HQ country
- Saudi Arabia
- HQ region
- Middle East
Offices2 records
Markets served
Lifera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Biomanufacturing CDMO Services: Contract development and manufacturing organization providing commercial-scale drug product and drug substance manufacturing services to pharmaceutical companies. Revenue generated through manufacturing fees, technology transfer agreements, and long-term supply contracts with global pharma clients. SaudiBio facility performs formulation, fill, labeling and packaging of biotherapeutics, vaccines, and other biologics.
- Omics and Genetic Testing Services: Genomic and multiomic testing services provided to clinical, population health programs, and pharmaceutical clients. Revenue derived from diagnostic testing, bioinformatics services, and research partnerships with healthcare systems and biopharma companies.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels2 records
Lifera product offering
Product offeringCore offering
Lifera provides commercial-scale contract development and manufacturing (CDMO) services for biopharmaceuticals through its subsidiary SaudiBio, covering drug substance and drug product manufacturing including formulation, aseptic filling, labeling, and packaging of biotherapeutics, vaccines, monoclonal antibodies, plasma therapeutics, cell and gene therapies, and innovative small molecules. The company also offers high-throughput genomic and multiomic testing, bioinformatics, and precision medicine services through Lifera Omics, supported by a proprietary biodatabank enriched for Saudi Arabian population genomics.
Product overview
Lifera is a biopharmaceutical company owned by Saudi Arabia's Public Investment Fund operating two primary business units: Biomanufacturing (including subsidiary SaudiBio) and Lifera Omics (MultiOmics). The Biomanufacturing division provides commercial-scale sterile drug product manufacturing services including formulation, fill, labeling, and packaging of biotherapeutics, vaccines, and other biologics, with SaudiBio Plant 1 targeting 120 million annual units capacity. The Lifera Omics platform delivers high-throughput genetic testing, bioinformatics, and precision medicine services powered by a proprietary biodatabank enriched for Saudi population genomic data. These offerings work together to enable end-to-end capabilities from genetic testing and drug discovery through commercial manufacturing of biologics, supporting Saudi Arabia's National Biotechnology Strategy and Vision 2030 goals.
Differentiator
Problem solved
Functional benefit
Brands
- SaudiBio: State-of-the-art biopharmaceutical manufacturing facility located in Sudair Industrial City, 110 km north of Riyadh. Specializes in commercial drug product manufacturing including formulation, fill, labeling, and packaging of vials, prefilled syringes, and cartridges in both liquid and lyophilized formats.
- Lifera Omics
Products and services
- Biomanufacturing Services (CDMO) State-of-the-art sterile and aseptic biopharmaceutical drug product and drug substance manufacturing services including formulation, fill, labeling, and packaging of biotherapeutics, vaccines, monoclonal antibodies, plasma therapeutics, cell and gene therapies, and innovative small molecules. Provided through the SaudiBio facility with isolator-based, fully automated cGMP-aligned filling lines and up to 120 million annual units capacity across liquid and lyophilized formats for vials, prefilled syringes, and cartridges. Targeted at global pharmaceutical companies seeking manufacturing localization.
- Lifera Omics (MultiOmics Testing and Bioinformatics Services) High-throughput genomic and multiomic testing, bioinformatics, and precision medicine services for clinical diagnostics, population health programs, and pharmaceutical research clients. Powered by a proprietary biodatabank with over 800,000 patients including 60,000+ Saudi Arabian individuals and 70+ million unique variants. Provided to healthcare providers, hospitals, research centers, and biopharma R&D teams in compliance with HIPAA, GDPR, and Saudi PDPL.
Quantifiable outcome
- Expected to create over 200 high-skilled jobs in Saudi Arabia by 2027/28 through Novo Nordisk insulin localization
- +2 more outcomes
Companies that use Lifera
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Lifera technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Lifera partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, major and strategic.
- Jamjoom PharmacoreJoint venture announced at Global Health Exhibition for development, manufacture, and commercialization of vaccines, biologics, and biosimilars in Saudi Arabia. Lifera holds 51% majority stake, Jamjoom Pharma holds 49% through subscription to 4,900 shares at SAR 100 per share. JV to build, own, and operate a manufacturing facility in Saudi Arabia. Transaction received no-objection certificate from General Authority for Competition.
- Pfizer Saudi ArabiamajorMoU signed at Global Health Exhibition 2025 to explore local pharmaceutical manufacturing opportunities in Saudi Arabia. Partnership supports Saudi Vision 2030 goals for biopharmaceutical industry development, technology transfer, and reducing reliance on pharmaceutical imports. Aims to position Saudi Arabia as a regional life sciences hub while strengthening Saudi-U.S. investment ties.
- SanofimajorMoU signed with Lifera to explore vaccine production opportunities in Saudi Arabia. Partnership announced at Global Health Exhibition 2025 as part of broader life sciences investments exceeding $625 million at the event.
- MSDmajorMoU signed with Lifera for localization and manufacturing of vaccines in the Kingdom, combined with knowledge and technology transfer to the Saudi workforce. Announced at Global Health Exhibition 2025.
- King Faisal Specialist Hospital & Research CentrestrategicPartnership signed at Global Health Exhibition 2025 to advance gene and cell therapy capabilities in Saudi Arabia. Collaboration aims to bring new expertise and technology into Saudi Arabia, strengthening national healthcare resilience.
- Novo Nordisk Saudi ArabiacoreSeven-year insulin localization partnership through Lifera's subsidiary SaudiBio. Novo Nordisk, the world's largest insulin producer, has agreed to localise insulin production in Saudi Arabia. Lifera will formulate, fill and finish insulin products. Saudi Arabia to become first producer of biologic innovator insulin in the region by 2027. Deal expected to create over 200 high-skilled jobs and facilitate technology transfer to Saudi workforce.
Scale indicators7 records
Recent moves6 records
Expansion highlights7 records
Lifera competitors and assessment
Company assessmentDirect peers
- Catalent: U.S.-based CDMO with deep expertise in sterile injectable fill-finish, prefilled syringes, and biologics. Comparable to Lifera as a peer in isolator-based aseptic filling and multi-format drug product manufacturing for vaccines and biologics.
- Lonza Group: Switzerland-based global CDMO leader in biologics, cell and gene therapies, and small molecules. Comparable to Lifera as a direct competitor for mammalian cell culture, fill-finish, and modality-diverse contract manufacturing contracts with global pharma.
- WuXi Biologics: China-based global biologics CDMO offering end-to-end services from cell line development to commercial manufacturing. Comparable to Lifera as a peer in scaling commercial biologics capacity, biosimilars, and end-to-end CDMO services for global pharma clients.
- FUJIFILM Diosynth Biotechnologies: U.S./U.K./Japan-based CDMO focused on biologics, vaccines, and gene therapy contract manufacturing. Comparable to Lifera in large-scale aseptic fill-finish, vaccine manufacturing, and process development for biologic modalities.
- Recipharm: Sweden-based CDMO with strong sterile injectable and prefilled syringe capabilities. Comparable to Lifera in aseptic fill-finish, drug product manufacturing, and contract services for biologics and complex injectables.
- Samsung Biologics: South Korea-based global biologics CDMO and one of the world's largest contract manufacturers of biopharmaceuticals. Directly comparable to Lifera as a from-scratch national champion building large-scale biologics capacity through sovereign backing, then scaling into a global CDMO.
- AGC Biologics: Global CDMO offering mammalian and microbial-based biologics manufacturing, with strong fill-finish capabilities. Comparable to Lifera in multi-modality biologics CDMO services, including for vaccines and biosimilars.
- Boehringer Ingelheim BioXcellence: Germany-based biologics CDMO specializing in mammalian cell culture, mAb production, and aseptic fill-finish. Comparable to Lifera as a peer in large-molecule biologics contract manufacturing, including for biosimilars and innovator biopharma.
Broad incumbents
- Thermo Fisher Scientific (CDMO / Patheon): Global life sciences giant offering comprehensive pharma services through its Patheon CDMO business, including sterile fill-finish and biologics. Comparable to Lifera as a broad incumbent CDMO competing for the same global pharma manufacturing contracts.
Regional players
- Arabio (Arabian Agricultural & Veterinary Medicines Company): Saudi Arabia-based pharmaceutical manufacturer producing vaccines, biologics, and veterinary products. Comparable to Lifera as a regional Saudi pharmaceutical manufacturer operating in the same domestic market for biologics and vaccine localization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Lifera social profiles
Digital presenceLifera compliance and trust
Trust signalCompliance4 records
Lifera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lifera leadership team
Management profileNumber of profiles
Profiles8 records
Lifera subsidiaries and ownership
Company hierarchySubsidiaries3 records
Lifera funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lifera M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lifera
What does Lifera do?
Lifera provides commercial-scale contract development and manufacturing (CDMO) services for biopharmaceuticals through its subsidiary SaudiBio, covering drug substance and drug product manufacturing including formulation, aseptic filling, labeling, and packaging of biotherapeutics, vaccines, monoclonal antibodies, plasma therapeutics, cell and gene therapies, and innovative small molecules. The company also offers high-throughput genomic and multiomic testing, bioinformatics, and precision medicine services through Lifera Omics, supported by a proprietary biodatabank enriched for Saudi Arabian population genomics.
Is Lifera a public or private company?
Lifera is a private company. It is classified as state government owned and is currently operating.
When was Lifera founded?
Lifera was founded in 2023. It employs 51 to 100 people.
Where is Lifera based?
Lifera is headquartered in Riyadh, Saudi Arabia, in the Middle East region.
How does Lifera make money?
Two revenue lines are on record. Biomanufacturing CDMO Services are the primary driver. The others are omics and Genetic Testing Services.
Who are Lifera's main competitors?
Direct peers on record are Catalent, Lonza Group, WuXi Biologics, FUJIFILM Diosynth Biotechnologies, Recipharm, Samsung Biologics, AGC Biologics and Boehringer Ingelheim BioXcellence. Thermo Fisher Scientific (CDMO / Patheon) is listed as a broad incumbent. Arabio (Arabian Agricultural & Veterinary Medicines Company) is listed as a regional player.
Does Lifera have an API?
No public API is recorded for Lifera.
What industry is Lifera in?
Lifera's product category is Biopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2834.